Once-Yearly Administered Intravenous Zoledronic Acid for Postmenopausal Osteoporosis

Woodis, C. B.

doi:10.1345/aph.1k652

Cited by 10 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ZA is a third-generation bisphosphonate molecule with highest potency among all the current commercially available bisphosphonates and is used in fragility fracture prevention. − Zoledronic acid decreases the BMP induced osteoclast activity, thus leading to a net increase in amount of bone . ZA can be incorporated into the NC matrix along with BMP, leading to codelivery of both the molecules directly at the defect site.…”

Section: Discussionmentioning

confidence: 99%

Nano-Hydroxyapatite Bone Substitute Functionalized with Bone Active Molecules for Enhanced Cranial Bone Regeneration

Teotia

Raina

Singh

et al. 2017

ACS Appl. Mater. Interfaces

113

View full text Add to dashboard Cite

The aim of this study was to synthesize and characterize a nano-hydroxyapatite (nHAP) and calcium sulfate bone substitute (NC) for cranioplasty. The NC was functionalized with low concentrations of bone morphogenetic protein-2 (BMP-2) and zoledronic acid (ZA) and characterized both in vitro and in vivo. In vitro studies included MTT, ALP assays, and fluorescent staining of Saos-2 (human osteoblasts) and MC3T3-E1 (murine preosteoblasts) cells cultured on NC. An in vivo study divided 20 male Wistar rats into four groups: control (defect only), NC, NC + ZA, and NC + ZA + rhBMP-2. The materials were implanted in an 8.5 mm critical size defect in the calvarium for 12 weeks. Micro-CT quantitative analysis was carried out in vivo at 8 weeks and ex vivo after 12 weeks. Mineralization was highest in the NC + ZA + rhBMP-2 group (13.0 ± 2.8 mm) compared to the NC + ZA group (9.0 ± 3.2 mm), NC group (6.4 ± 1.9 mm), and control group (3.4 ± 1.0 mm) after 12 weeks. Histological and spectroscopic analysis of the defect site provided a qualitative confirmation of neo-bone, which was in agreement with the micro-CT results. In conclusion, NC can be used as a carrier for bioactive molecules, and functionalization with rhBMP-2 and ZA in low doses enhances bone regeneration.

show abstract

Section: Discussionmentioning

confidence: 99%

Nano-Hydroxyapatite Bone Substitute Functionalized with Bone Active Molecules for Enhanced Cranial Bone Regeneration

Teotia

Raina

Singh

et al. 2017

ACS Appl. Mater. Interfaces

113

View full text Add to dashboard Cite

show abstract

“…IV bisphosphonates (ibandronate or ZA) are useful for patients who cannot tolerate an oral bisphosphonate. Once yearly IV ZA 5 mg is convenient and leads to faster and greater reduction in bone turnover markers than weekly oral alendronate (Woodis, 2008). However, 10%-50% of patients experience an acute phase reaction with flu-like symptoms that start about 24-36 hours after the first infusion of ZA and resolve in two or three days (Bertoldo et al, 2010).…”

Section: Bisphosphonatesmentioning

confidence: 99%

Osteoporosis Related to Disease or Therapy in Patients With Cancer

Wickham¹

2011

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Osteoporosis is a major public health issue in the general population, particularly in postmenopausal women. Patients with cancer may not only be at risk for primary osteoporosis, but for secondary osteoporosis related to cancer therapies-particularly therapies that impair gonadal function, lead to loss of serum estrogen, and negatively affect bone turnover. Normal bone remodeling is influenced by the receptor activator for nuclear kappa-B ligand pathway, calcium, vitamin D, and other nutrition factors, as well as modifiable and nonmodifiable factors. Identifying which patients with cancer are at risk for bone mineral density loss is important and may include patients with breast or prostate cancer, some survivors of pediatric malignancies, and adults with other tumors. Nurses play a major role in identifying those patients and their risk for low-impact fractures, which can have a significant effect on patient morbidity and mortality. Counseling and teaching are central nursing functions, as well as safely administering therapies, particularly bisphosphonates and denosumab.

show abstract

“…Thus, the findings support the assumption that ZLN released from implants in the peritoneum effectively treats the examined long bones. In clinic, once-yearly intravenous ZLN treatment is recommended to treat patients with osteoporosis [25]. Bolland et al reported that the effects of intravenous ZLN persisted for at least 24 months in terms of bone turnover and BMD [51].…”

Section: Discussionmentioning

confidence: 99%

“…The second method is intravenous, administrating the third-generation bisphosphonate zoledronate (ZLN), and is commonly used. It was selected in this study because of its sustained in vivo performance [25]. However, a HORIZON study reported adverse events in up to 78% of cases after intravenous ZLN treatment.…”

Section: Introductionmentioning

confidence: 99%

Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats

Wu¹,

Wang²,

Lu³

et al. 2012

Biomed. Mater.

View full text Add to dashboard Cite

Patients sustaining bony fractures frequently require the application of bone graft substitutes to fill the bone defects. In the meantime, anti-osteoporosis drugs may be added in bone fillers to treat osteoporosis, especially in postmenopausal women and the elderly. The effects of zoledronate-impregnated calcium phosphate cement (ZLN/CPC) on ovariectomized (OVX) rats were evaluated. OVX rats were implanted with ZLN/CPC, containing 0.025 mg ZLN in the greater omentum. Afterward the clinical sign of toxicity was recorded for eight weeks. The rats were sacrificed and blood samples were collected for hematology and serum bone turnover markers analyses. The four limbs of the rats were harvested and micro-computer tomography (micro-CT) scanning and bone ash analyses were performed. No clinical toxicity was observed in the treated rats. Compared to the OVX rats, levels of bone resorption markers (fragments of C-telopeptides of type I collagen) and bone formation markers (alkaline phosphatase and osteocalcin) decreased significantly in the treated rats. Osteopontin, which mediates the anchoring of osteoclasts to the mineral matrix of bones, also decreased significantly. Micro-CT scanning and histologic examinations of the distal femoral metaphyses showed that the cancellous bone architectures were restored, with a concomitant decrease in bone porosity. The bone mineral content in the bone ashes also increased significantly. This study indicates that ZLN-impregnated CPC reduces bone turnover rate and restores bone architecture in OVX rats. CPC may be an appropriate carrier to deliver drugs to treat osteoporosis, and this approach may also reduce rates of post-dosing symptoms for intravenous ZLN delivery.

show abstract

Once-Yearly Administered Intravenous Zoledronic Acid for Postmenopausal Osteoporosis

Cited by 10 publications

References 15 publications

Nano-Hydroxyapatite Bone Substitute Functionalized with Bone Active Molecules for Enhanced Cranial Bone Regeneration

Nano-Hydroxyapatite Bone Substitute Functionalized with Bone Active Molecules for Enhanced Cranial Bone Regeneration

Osteoporosis Related to Disease or Therapy in Patients With Cancer

Calcium phosphate cement delivering zoledronate decreases bone turnover rate and restores bone architecture in ovariectomized rats

Contact Info

Product

Resources

About